Catalyst Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Yahoo! Finance
19.8% y/y) that exceeded guidance and provided 2026 revenue guidance of $615–$645 million with product-level targets: Firdapse $435–450M AGAMREE $140–150M , and Fycompa $40–45M (no longer promoted due to generics). Firdapse remains the growth engine , generating $358.4 million in 2025 (+17%); management credited expanded patient identification, a 33% increase in VGCC testing, and a pharmacy outreach program that cut early discontinuations by ~12%, while penetration is ~30% in idiopathic LEMS and under 10% in cancer-associated LEMS. AGAMREE adoption accelerated , delivering $117.1 million in 2025 (up 154%), with enrollment at 100% of top DMD centers of excellence, reimbursement success above ~85–90%, and ongoing SUMMIT and Phase I studies with analyses expected in H1 2026 to support lifecycle plans. Interested in Catalyst Pharmaceuticals, Inc.? Here are five stocks we like better. 2 Biotechs Making Waves With A Single Product in their Pipeline Catalyst Pharmaceuticals (NASDAQ
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Catalyst Pharmaceuticals (CPRX) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- Catalyst Pharmaceuticals (CPRX) had its price target raised by Citigroup Inc. from $33.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results [Yahoo! Finance]Yahoo! Finance
- Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Its Strong DCF Upside After Recent Flat Returns [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
CPRX
Earnings
- 2/25/26 - Beat
CPRX
Sec Filings
- 2/25/26 - Form 8-K
- 2/25/26 - Form 10-K
- 2/19/26 - Form 4
- CPRX's page on the SEC website